Clinical and Radiographic Success of MTA vs Biodentine
Recruiting
Phase 4
Interventional Study
Indirect Pulp Cap
Pulpotomy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 2 – 12
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 646 (estimated)
- Sponsor
- Geisinger Clinic · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male or female patients ages of 2 to ≤12 years.
* Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.
* Patient who need a pulpotomy and/or indirect pulp cap treatments in two or more quadrants.
* Parents of patients who can p…
Contacts